LumiGene Inks Reverse Acquisition Pact with Pole Perfect; Dances into Public Market

Upon completion of the acquisition, the combined company's focus will be strictly on Lumigene's business of developing diagnostics using its nucleic acid amplification platform.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories